Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Gorf79on Jul 12, 2022 2:03pm
188 Views
Post# 34818642

pectoral’ Partners - For New Investors

pectoral’ Partners - For New InvestorsForget the bashing nonsense and wrap your head around the 40 cent share price in the context of Spectral's partners detailed below:

Baxter- North American Commercialization partner for their PMX sepsis treatment

Infomed of Switzerland - Manufacturers of the Paradigm Shifting Sami and DIMI dialysis units, for which Spectral has 100% NA marketing rights

Estor - European distributor on EAA

Toray Medical of Japan- a major Japanese pharma which has granted Spectral the North American rights to the PMX Sepsis treatment

15 Household Brand Name US hospitals confucting the current Confirmatory PMX Sepsis treatment trial.

Da Vita - "The name" in dialysis treatment! Soon to be announced as the partner for the DIMI home use trial.

ARC Dialysis -Thrir first commercialization partner for SAMI and the largest dialysis provider in the South Eastern US

University of Michigan - DIMI home use partner and the first adopter of  the fully FDA approved SAMI 

The Food And Drug Administration!!!- Yes Sir - There is an enormous need for PMX and they have acknowledged that throughout the trial process and have held Spectral's hand all the way through this trial process. Breakthrough Therapy is the most recent exemple of the FDA's commitment to guiding Spectral to PMX approval for the treatment of Sepsis.

Wrap your head around that in the context on a 40 cent share price.

Maybe now you'll understand why I have been buying with both hands for nearly 2 decades!!!
<< Previous
Bullboard Posts
Next >>